Amgen Inc. has offered to buy Denmark-based drug discovery platform biotech company, Nuevolution, at $3.36 per share in cash. Amgen’s offer is a169% premium over the closing price of Nuevolution shares on May 21, valuing it at approximately $167 million. The shares of Nuevolution are listed on the Nasdaq Stockholm Small Cap exchange.
The board of Nuevolution unanimously recommended an acceptance of the offer and three top shareholders, representing 59% shareholdings, have also undertaken to accept the offer. Amgen expects to settle the offer by Jul 15.